A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1TPS ≥50%
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: MK-1084 Pembrolizumab
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Giuseppe Lo Russo
This clinical trial will evaluate the KRAS G12C mutation inhibitor, MK-1084, in combination with pembrolizumab versus placebo plus pembrolizumab as first-line treatment of metastatic NSCLC positive for the KRAS G12C mutation with PD-L1 TPS ≥50%.
The study comprises 2 treatment arms:
- Arm A: Pembrolizumab + MK1084
- Arm B: Pembrolizumab+ placebo
Last update: 20/05/2025